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Background: Strategies to protect the brain from postoperative delirium (POD) after hip fracture are urgently
needed. The development of delirium often is associated with the loss of independence, poor functional recovery,
and increased morbidity, as well as increases in length of hospital stay, discharges to nursing facilities, and
healthcare costs. We hypothesize that xenon may reduce the burden of POD, (i) by avoiding the need to provide
anesthesia with a drug that targets the γ-amino-butyric acid (GABA)A receptor and (ii) through beneficial anesthetic
and organ-protective effects.
Methods and design: An international, multicenter, phase 2, prospective, randomized, blinded, parallel group and
controlled trial to evaluate the incidence of POD, diagnosed with the Confusion Assessment Method (CAM), in
older patients undergoing hip fracture surgery under general anesthesia with xenon or sevoflurane, for a period of
4 days post surgery (primary outcome) is planned. Secondary objectives are to compare the incidence of POD
between xenon and sevoflurane, to evaluate the incidence of POD from day 5 post surgery until discharge from
hospital, to determine the time to first POD diagnosis, to evaluate the duration of POD, to evaluate the evolution of
the physiological status of the patients in the postoperative period, to evaluate the recovery parameters, to collect
preliminary data to evaluate the economical impact of POD in the postoperative period and to collect safety data.
Patients are eligible if they are older aged (≥ 75 years) and assigned to a planned hip fracture surgery within 48 h
after the hip fracture. Furthermore, patients need to be willing and able to complete the requirements of this study
including the signature of the written informed consent. A total of 256 randomized patients in the 10 participating
centers will be recruited, that is, 128 randomized patients in each of the 2 study groups (receiving either xenon or
sevoflurane).
Trial registration: EudraCT Identifier: 2009-017153-35; ClinicalTrials.gov Identifier: NCT01199276
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Postoperative delirium (POD) is an acute confusional state
associated with changes in consciousness, arousal level and
cognitive status characterized by inattention within 30 days
after an operation [1] and occurs in 15 to 53% of older
patients [1,2] particularly in those with hip fractures [1,3].
We have recently conducted a meta-analysis showing that
delirium associated with hip fracture doubles the hazard
ratio of death (HR 2.3 95% CI 1.4 to 3.9) [1]. Furthermore
the development of delirium often initiates a cascade of
events culminating in the loss of independence, poor func-
tional recovery, and increased morbidity, as well as
increases in length of hospital stay, discharges to nursing
facilities, and healthcare costs [1-6].
The pathogenesis of delirium is poorly understood
though Sanders has proposed that delirium can be con-
sidered as a ‘cognitive disintegration’ whereby the inte-
grated neural function of the brain is broken down
producing a varied range of symptoms focused on con-
sciousness, arousal and memory [7]. Within the pro-
posed framework various non-modifiable patient risk
factors are hypothesized to contribute to reduced net-
work connectivity (a surrogate for integration) at base-
line, for example, age [7]. Modifiable risk factors
(including inflammation and sedative drugs) act to fur-
ther decrease network integration in the brain through
altering the balance of neural transmission predomin-
antly through increases in inhibitory tone mediated by
γ-amino-butyric acid (GABA) signaling in the brain [7].
A prediction of this theory is that avoidance of GABAer-
gic drugs, that include the majority of anesthetic (for ex-
ample, sevoflurane or propofol) and sedative agents,
would reduce the burden of postoperative and intensive
care delirium.
In parallel, research showing multiple beneficial effects
of the non-GABAergic anesthetic agent xenon has been
published. As an inert, noble gas, xenon is not metabo-
lized by the body but yet exerts myriad biological effects,
the most notable being anesthesia and organ protection
[8-18]. Xenon is thought to produce anesthesia through
targeting either excitatory N-methyl-D-aspartate or two-
pore-domain-potassium channels but not GABAA recep-
tors [8,9,13]. Xenon anesthesia is rapid onset, cadiostable
and xenon is not thought to disturb autoregulation of
organ blood flow [8,9,13]. Furthermore, xenon protects
the brain, heart and kidney from diverse toxic insults
including ischemia [8,9,13,18]. Xenon exerts a diverse
array of neuroprotective effects (for example, induction
of B-cell lymphoma-extra large (Bcl-xl), phosphorylated
cAMP response element binding protein (pCREB) and
hypoxia-inducible factor (HIF)-1α cell survival proteins)
[11,12,18] and importantly synergizes with other neuro-
protective strategies (for example, hypothermia and α2
agonists) [10,11,19].We therefore hypothesize that xenon may reduce the
burden of POD (i) by avoiding the need to provide
anesthesia with a drug that targets the GABAA receptor
and (ii) through beneficial anesthetic and organ-protective
effects. Based on our hypotheses we designed a multicenter
European randomized controlled trial comparing xenon
with sevoflurane anesthesia.
Our working hypotheses are: (1) xenon may contribute
to a lower incidence of POD as compared to sevoflurane,
within 4 days post surgery; (2) xenon may contribute to
reduce postoperative organ dysfunction; and (3) xenon
may reduce healthcare costs associated with POD.
Methods and design
The design of the study was approved by the clinical
ethical review committee (Clinical Ethical Review Com-
mittee; Medical Faculty; RWTH Aachen; EK 050/10)
and by the local ethical review committees of the partici-
pating centers and by the competent authorities of the
five participating countries prior to patient recruitment.
Study centers
This trial was designed to include the following ten in-
vestigational centers: Department of Anaesthesiology,
University Hospital Aachen, Aachen, Germany; Depart-
ment of Anaesthesia, Imperial College London & Imperial
College NHS Trust, London, UK; Department of Anaesthe-
sia and Surgical Care, Hospital Clínico Universitario de
Valencia, Valencia, Spain; Department Modul of Research
in Anaesthesia, IRCCS Rizzoli Orthopaedic Institute,
Bologna, Italy; Department of Anaesthesia and Surgical
Intensive Care, Groupe Hospitalier Cochin Saint Vincent
de Paul, Paris, France; Department of Anaesthesia, Centre
Hospitalier et Universitaire de Grenoble, Hôpital Michallon,
La Tronche, France; Department of Anaesthesia, Centre
Hospitalier Régional Universitaire de Montpellier, Hôpital
Lapeyronie, Montpellier, France; Department of Anaesthe-
sia and Intensive Care Medicine, Centre Hospitalier et
Universitaire de Toulouse, Hôpital Rangueil, Toulouse,
France; Department of Anaesthesia, University Hospital
Düsseldorf, Düsseldorf, Germany; Department of Anaesthe-
sia, Emergency and Intensive Care Medicine, Klinikum
Mutterhaus der Borromäerinnen gGmbH, Trier, Germany.
Methodology
This phase 2 study is an international, multicenter, pro-
spective, randomized, blinded, parallel group and con-
trolled trial.
Objectives
The primary objective of this study is to evaluate the in-
cidence of POD, diagnosed with the Confusion Assess-
ment Method (CAM; see Additional file 1) [20], in older
patients undergoing hip fracture surgery under general
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days post surgery. The secondary objectives of this study
are: to evaluate the incidence of POD from day 5 post
surgery until discharge from hospital; to determine the
time to first POD diagnosis; to evaluate the duration of
POD; to evaluate the evolution of the physiological sta-
tus of the patients in the postoperative period; to evalu-
ate the recovery parameters; to collect preliminary data
to evaluate the economical impact of POD in the post-
operative period; and to collect safety data.Number of patients
A total of 256 patients will be included in this clinical
trial. After having received local ethics committee and
national competent authority approvals, patients are
being recruited. Each patient who accepts to participate
in the study will sign the written informed consent be-
fore performing any study specific procedure.Inclusion and exclusion criteria
The criteria for inclusion are: older patient (≥ 75 years);
patient with planned hip fracture surgery within 48 h
after the hip fracture; patient willing and able to
complete the requirements of this study, including the
signature of the written informed consent.
The criteria for exclusion are: patient suffering from
multiple fractures, pelvic fractures proximal, pathological
fractures, femur fractures (that is, fractures of the middle
or distal femur); disabling neuropsychiatric disorders
(severe dementia, Alzheimer’s disease, schizophrenia, de-
pression); brain trauma within 12 months prior to selec-
tion, history of stroke with residuals; patient suffering
from delirium (CAM diagnosis) at selection; patient who
cannot complete the preoperative mental tests (CAM
and/or Mini-Mental State Examination (MMSE)) of this
clinical trial; patient with MMSE score < 24 at selection;
patient known to susceptible to malignant hyperthermia;
patient with elevated intracranial pressure; patient with aFigure 1 Study flow chart of the Hip Fracture Surgery in Elderly Patie
anesthesia.risk of high oxygen demand; patient with recent (less than
1 month) or ongoing myocardial infarction/damage; pa-
tient with severe cardiac failure or patient with severe
impaired left ventricular systolic function; patient with
known severe lung and/or airway disease, or severe chronic
respiratory insufficiency, or a sustained homecare oxygen
therapy; contraindication (serious illness or medical condi-
tions) for general anesthesia; known allergy or hypersensi-
tivity to any drugs administered during this clinical trial;
previous participation in this clinical trial; participation in
another clinical trial within 4 weeks prior to selection, or
concurrent treatment with any other experimental drugs;
history of alcohol or drug abuse or psychiatric disorders
that would impair the understanding of the necessary infor-
mation or render medically or legally unable to give written
informed consent.Investigational plan and treatments
Eligible patients will be randomly assigned to one of the
two study groups (group A: xenon 60% (55% to 65%; 1 min-
imal alveolar concentration (MAC)) in oxygen (FiO2 = 0.35
to 0.45) or group B: sevoflurane 1.1% to 1.4% (1 MAC) in
oxygen (FiO2 = 0.35 to 0.45) and medical air). Throughout
the study, there will be two teams of physicians involved in
the patient’s follow-up (see Figure 1).
Physician 1 will perform visits 0, 2, 3, 4, 5, 6, 7 and 8,
which includes selection of patients, follow-up visits and
study end visit. Physician 1 will be kept blinded regard-
ing the natures and doses of all study drugs administered
throughout the study (Table 1 and Figure 1).
Physician 2 will perform visit 1, which includes
randomization and surgical procedure under general
anesthesia.Pre-anesthetic assessment (visit 0, physician 1)
Within 48 h before their general anesthesia, cognitive
function of each patient will be assessed with the
MMSE, the presence of delirium will be diagnosed withnts (HIPELD) study. V = visit; d = day; hrs = hours, GA = general
Table 1 Study evaluations
Visit 0a
(selection)
Visit
1b
(GA)
Visit
2a (3
h
post
GA)
Visit 3a
(day 1)
Visit 4a
(day 2)
Visit 5a
(day 3)
Visit 6a
(day 4)
Visit 7a (day 5 to D) Visit 8a (study end)
A B A B A B A B A B
Signed informed consent X
Selection criteria X
Demographic data X
Vital signs X X X X X X X X
Medical and surgical history X
Concomitant diseases X
Concomitant medication X X X X X X X X X X X X X X
MMSE evaluation X
Randomization X
General anesthesia X
Blood sample X X X X X According to
investigator’s
judgment
CAM evaluation X X X X X X X X X X X X
Pain VAS evaluation X X X X X X X
Verbal Rating Scale for Nausea X X X
SOFA X X X X X According to
investigator’s
judgment
Recovery parameters X
Adverse events X X X X X X X X X X X X X
A represents 10:00 am ± 30 minutes; B represents 6:00 pm ± 30 minutes; day 5 to D is post-surgery day 5 until discharge from hospital (or at maximum 28 days
post surgery), or withdrawal from the study.
aPhysician 1; bPhysician 2.
CAM = Confusion Assessment Method; GA = general anesthesia; MMSE = Mini-Mental State Examination; SOFA = Sequential Organ Failure Assessment; VAS =
visual analog scale.
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(SOFA) score (Additional file 2: Table S1) [21,22]and
level of pain on a 100-mm visual analog scale (VAS) will
be assessed. Moreover, a 12-lead electrocardiogram
(ECG) will be performed and a blood sample will be col-
lected to assess laboratory parameters. Premedication
for general anesthesia will be avoided before surgery,
and no premedication impairing cognitive function will
be administered on the day of the surgery. Of note, all
investigators have been trained to use the CAM and all
other test used in this trial.
Surgical procedure under general anesthesia:
randomization (visit 1, physician 2)
Patients must be on fasting state the day of the surgery, at
least 6 h prior to anesthesia for solids and 3 h for liquids.
Patients will be monitored continuously, and the corre-
sponding measurements will be recorded every 5 minutes,
for the following standard safety parameters: non-invasive
blood pressure measurements (NIBP; that is, systolic and
diastolic blood pressures), ECG monitoring, transcutaneousmeasurements of arterial oxygen (O2) saturation and end-
tidal carbon dioxide (CO2) concentration, from the pre-
anesthetic period to the end of general anesthesia. Body
temperature will be monitored continuously. Patients will
be equipped with a bispectral index (BIS) monitor for the
depth of anesthesia, as well as with a monitoring device
for the neuromuscular relaxation on their skin covering
the adductor pollicis muscle. Physician 2 will take into
account the neuromuscular relaxation monitoring to de-
termine (i) the appropriate time for the patient’s endo-
tracheal intubation, (ii) needs of repeated bolus injection
of cis-atracurium during the maintenance period and (iii)
appropriate time for the anesthesia discontinuation.
A registration number in sequential numerical order
in each center separately will be assigned to each eligible
patient. Before induction, physician 2 will open the indi-
vidual randomization envelope allocated to the patient
in order to prepare all equipment required and study
drugs needed during the general anesthesia. Prior to the
study start, one randomization list has been pre-
established on computer by the sponsor.
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Preoxygenation will be performed using oxygen (FiO2 =
1.0) in all patients.
Balanced anesthesia will be induced by the combin-
ation of intravenous injection of propofol administered
at 1 to 2 mg/kg by bolus titration; intravenous injection
of remifentanil administered at 0.5 μg/kg via infusion
pump continuously; and for tracheal intubation, non-
depolarizing neuromuscular blocking agents, that is,
intravenous injection of cis-atracurium will be adminis-
tered at 0.1 mg/kg once the depth of anesthesia is con-
sidered sufficient (40 ≤BIS Index ≤60). The internal cuff
pressure measurements will be recorded every 5.
Maintenance of anesthesia
The administration of xenon or sevoflurane (according
to the randomized study group assigned to the patient)
will be started in the automatic mode (Felix DualTM
workstation; Air Liquide, Paris, France) to reach a target
concentration of 60% (55% to 65%) of xenon, or 1.1% to
1.4% of sevoflurane. About 10 minutes should be suffi-
cient to reach this target concentration. This 10-minute
period will be covered with a total intravenous propofol
infusion at 0.05 to 0.15 mg/kg/min.
Then, the administration of propofol will be stopped.
Simultaneously the xenon or sevoflurane will be admi-
nistered in the economic mode (Felix DualTM worksta-
tion) for all patients to maintain the following target
concentration according to randomized study group
assigned to the patient: group A: xenon 60% (55% to
65%) (1 MAC) in oxygen (FiO2 = 0.35 to 0.45), group B:
sevoflurane 1.1% to 1.4% (1 MAC) in oxygen (FiO2 =
0.35 to 0.45) and medical air.
Whatever their randomized study group assigned,
patients will receive intravenous injection of remifentanil
via infusion pump at an initial rate of 0.15 μg/kg/min,
then titrated to the clinical needs. In addition intraven-
ous bolus injections of cis-atracurium at 0.025 mg/kg
will be administered according to physician 2’s
judgment.
Monitoring throughout the anesthesia
Systolic blood pressure should be kept ≥ 100 mmHg (or
≥ 60 mmHg for mean arterial blood pressure), and a
relative variation > 20% from baseline values has to be
avoided by administering rescue medication. The ECG
will be monitored continuously and heart rate should be
kept between 60 and 100 beats per minute. The type
and duration of any new spontaneous arrhythmias
should be recorded as adverse events. Ventilation will be
adjusted to maintain an end-tidal CO2 level between 36
and 45 mmHg. Body temperature will be maintained be-
tween 36.0°C and 37.0°C. Depth of anesthesia will be
continuously monitored with BIS VISTATM monitoringsystem (Covidien, Dublin, Ireland) and should be kept in
a range between 40 and 60 to maintain a sufficient depth
of anesthesia. Within the last 45 minutes before the
expected skin closure, no additional cis-atracurium in-
jection shall be administered, in order to ensure suffi-
cient spontaneous ventilation prior to extubation. In
addition, administration of acetylcholinesterase inhibi-
tors should be avoided.Rescue treatments
If autonomic activity (defined as sweating, salivation,
flushing), somatic signs (defined as movement and swal-
lowing), or hemodynamic signs (defined as a change in
systolic blood pressure or heart rate more than 20%
from baseline in the absence of hypovolaemia) become
evident corrective treatments will be administered
according to physician 2’s judgment.
Antihypertensive and inotropic agents are allowed if
the heart rate or blood pressures indicate their neces-
sary use. Appropriate blood and/or fluid replacement
strategy is to be used according to physician 2’s judg-
ment. Analgesia, including additional locoregional anal-
gesia, will also be administered according to physician
2’s judgment.Wake up
At 10 minutes before the expected end of all surgical
procedures, the inhaled anesthetic agents will be reduced
to 0.5 MAC. After the effective skin closure, the Train of
Four (TOF) test will be performed to exclude existing
neuromuscular relaxation. From this timepoint, ad-
equate spontaneous ventilation has to be ensured and
end-tidal carbon dioxide level is allowed to increase up
to 50 mmHg. Recovery parameters, namely time to open
eyes, time to react on verbal command, time to extuba-
tion and time to spatial orientation, are to be recorded.Post-anesthesia care unit (PACU)
The patients will be transferred to the PACU (if neces-
sary, patients will be discharged directly to intermediate
care or intensive care units) for continuous vital signs
monitoring (NIBP, ECG and transcutaneous measure-
ments of arterial oxygen saturation. Every 15 minutes,
the vital signs and Aldrete score will be recorded until
patients are considered ready to discharge from the
PACU, that is, when their Aldrete score reaches a value
≥ 9 (Additional file 3: Table S2) [23]. Postoperative nau-
sea and vomiting (PONV) and blood loss will be
assessed. The timepoint of this last evaluation of the
Aldrete score will be considered as the end time of the
recovery period, that is, the time to readiness to be dis-
charged from the PACU.
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Once the patient is able to evaluate his/her pain on a
100-mm VAS, postoperative analgesia (including add-
itional locoregional analgesia) will be administered
according to the local procedures of each participating
center, in order to maintain a VAS pain score ≤ 30 mm.
The administration of oral or intravenous non-steroidal
anti-inflammatory drugs (NSAIDs), as well as opioids in
the regional anesthesia, will be avoided.
PONV management
Once the patient is able to evaluate his/her nausea on a
11-point verbal rating scale (VRS, Additional file 4)
(with 0 corresponding to no nausea and 10 correspond-
ing to nausea as bad as it could be) [24], Dexamethasone
8 mg and/or a 5HT3-antagonist (such as ondansetron 4
mg administered every 6 h if necessary) will be adminis-
tered if the patient is retching or vomiting or if his/her
VRS for nausea is > 3; see Additional file 4.
Postoperative blood and/or fluid loss management
The blood and/or fluid replacement strategy is to be
used according to physician 2’s judgment.
Follow-up visits (visits 2 to 7, physician 1)
All randomized patients will be followed up from 3 h to
discharge from the hospital (or at maximum 28 days
post surgery), or withdrawal from the study. The 4 days
following the surgery, CAM, VAS, SOFA and laboratory
results, including platelets count, serum hemoglobin,
hematocrit, leucocytes, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), γ- glutamyl-
transferase, total bilirubin, serum creatinine and urea
concentrations, troponin I or troponin T, C-reactive pro-
tein, serum sodium and potassium and serum glucose
concentration will be recorded. From day 5 onwards,
SOFA and laboratory results become optional. Vital
signs, concomitant medications, adverse events and ser-
ious adverse events are obtained in all study visits.
Details of the study evaluations performed are presented
in Table 1.
Evaluation criteria
The primary efficacy criterion is POD diagnosed via
CAM at least once within 4 days post surgery.
The secondary efficacy criteria include: (1) POD diag-
nosed with the CAM from day 5 post surgery to dis-
charge from hospital; (2) SOFA from day 1 to day 4 post
surgery; (3) recovery parameters; (4) economic para-
meters, which are addressed to evaluate the economical
impact of POD in the postoperative period from the
hospital perspective; (5) safety: adverse events and ser-
ious adverse events, and laboratory parameters.Safety evaluations
All adverse events (AEs) occurring during the whole
study period will be recorded by the investigators. Phys-
ician 1 will record all AEs apart from those occurring on
the day of the surgery, between the time of admission of
the patients in the operating room to the time of dis-
charge of the patients from the PACU. The information
recorded in the case report forms for each AE experi-
enced by the patients throughout their whole study
period will include the nature of the events, their onset
date and time, their end date and time, their severity,
the corrective treatment(s) started if applicable, the out-
come of the events and their relationship to the investi-
gational inhaled gas and to the intravenous line applied
separately as assessed by the investigator who records
the AE. Physician 1 will record the relationships of each
AE described to the investigational inhaled gas and to
the intravenous line applied separately without knowing
the nature of the study drugs administered.
Economic parameters
Time to readiness to be discharged from the operating
room, effective times of admission and discharge from
the operating room, onset and end times of the general
anesthesia and surgical procedure (onset and end times
of induction, time of intubation, onset and end times of
the administration of the study treatments, time of skin
incision and end of wound dressing, time of extubation),
total drugs (xenon or sevoflurane) consumption per pa-
tient, are to be recorded by Physician 2, as well as the
type of hip fracture surgery performed (such as total hip
replacement, hemiarthroplasty of the hip, dynamic hip
screw, cemented or not cemented).
Statistical methods
The main analysis of the primary efficacy criterion will
correspond to the primary objective of the study which
is to evaluate the incidence of POD, diagnosed via CAM,
in older patients undergoing hip fracture surgery under
general anesthesia with xenon or sevoflurane, for a
period of 4 days post-surgery. All data collected will be
tabulated descriptively by group on the intention to treat
(ITT) dataset (which will be composed of all randomized
patients). The number of patients having being diag-
nosed POD with the CAM at least once throughout
their study participation from visit 2 to visit 6 will be
calculated in each group, and this number of patients
will be divided by the total number of participating
patients of the corresponding group. This ratio which
represents the rate of POD diagnosed within 4 days post
surgery will be compared between both groups, using
the Pearson’s χ2 test and its calculation provided by the
FREQ procedure of the current version of the SAS soft-
ware (SAS, Cary, NC, USA), on the ITT dataset.
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time elapsed between the onset of the maintenance
period of the general anesthesia and the first POD diag-
nosis with the CAM post surgery (expressed in full
number of started hours) will be tabulated by group, as
both quantitative and categorical data, in the subgroup
of patients for whom POD is diagnosed at least once
within 4 days post surgery. Time to first POD diagnosis
with the CAM post surgery will also be described glo-
bally by group, on the ITT dataset, using Kaplan-Meier
estimates to display the probability of survival and of
being diagnosed POD. Survival times will be censored at
the time of the patients’ last contact (in the subgroup of
patients for whom POD is never diagnosed within their
trial participation post surgery) or at the time of the first
POD diagnosis with the CAM (in the subgroup of
patients for whom POD is diagnosed at least once within
their trial participation post surgery). If relevant, times
to first POD diagnosis with the CAM post surgery will
be compared between both groups with the Log rank
test.Sample size calculation
We assume an expected rate of 30.0% of POD diagnosed
with the CAM at least once within 4 days post surgery
on sevoflurane, see Table 2 [3,25-32]. We hypothesize a
reduction of 50% to a rate of 15.0% of POD on xenon.
The type I error is set to be α = 0.05 (two-sided condi-
tions) and the power (1 - β) equals 0.80. Taking the
above-mentioned facts into consideration, the sample
size calculation results in 121 patients per group (the es-
timation is based on the two-group χ2 test of equal pro-
portions). With an expected 5.0% dropout rate over 4
days post surgery, 256 patients will be randomized in
this trial, that is, 128 patients in the xenon and 128
patients in the sevoflurane group. The sample size calcu-
lation was performed using nQuery AdvisorW Version
6.01 (Statistical Solutions, Saugus, MA, USA).Table 2 Incidence of postoperative delirium
Author Study type Patients Age
Marcantonio E, 2001 [26] RCT 64
Marcantonio E, 2002 [27] PCS 122
Marcantonio E, 2002 [28] PCS 126
Furlaneto M, 2006 [3] PCS 106
Zakriya K, 2002 [29] PCS 168
Zakriya K, 2004 [30] PCS 92
Sharma P, 2005 [31] PCS 47
Galanakis P 2001 [32] PCS 37
This table is an excerpt from studies assessing delirium with the CAM. Based on the
CAM = Confusion Assessment Method; PCS = prospective cohort study; RCT = randStudy monitoring, audit and inspection
The study will be monitored regularly (visits and tele-
phone monitoring) by Air Liquide Santé International
personnel or any company appointed by the latter. Dur-
ing the monitoring visits, the clinical research associate
(CRA) will verify the consistency of the data recorded
on the case report forms with the source documents
(patient’s medical file, nurse’s chart, and so on). The
CRA will also verify the management of therapeutic
batches, the presence and completeness of the investiga-
tor file and general study compliance with good clinical
practice guidelines. An on-site audit may be requested
and performed by the sponsor or designee personnel at
any time.Discussion
To date, 121 patients have been randomized (July 2012)
in this phase 2 study. Inclusion of patients is approxi-
mately 50% slower than expected. For this reason the re-
cruitment period of this trial was extended from the end
of 2012 to the end of 2013. Furthermore, three new sites
will be selected. Approximately two out of ten screened
patients have been included so far. This is due to the
strict inclusion and exclusion criteria especially cognitive
impairment (MMSE < 24), dementia or depression.
However, in this phase 2 study we need to keep above-
mentioned inclusion and exclusion criteria to be able to
show efficacy. We are awaiting the results of this trial to
anticipate a phase 3/4 trial, which would have different
inclusion and exclusion criteria including patients with
reduced capacity. The primary objective of this study is
to evaluate the incidence of postoperative delirium, diag-
nosed with the CAM, in older patients undergoing hip
fracture surgery under general anesthesia with xenon or
sevoflurane, for a period of 4 days post surgery. Post-
operative delirium occurs predominantly in the first 4
days following hip fracture surgery [25], during this
period it declines rapidly (peak on day 1, and on day 4).(years) Method Incidence Comments
>65 CAM 50% Total (n = 126)
>65 CAM 40% Subanalysis of [25]
>65 CAM 41% Subanalysis of [25]
>65 CAM 29.1%
>65 CAM 28%
>65 CAM 28%
>56 CAM 36%
>60 CAM 40.5%
se data the power for this study has been calculated.
omized controlled trial.
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unlikely to be due to the anesthetic technique; therefore
we only included the first 4 days for the primary end-
point. Furthermore the CAM is validated for use in
older patients [33]. A big effort was made to design this
study in s double blinded way and to keep the non-
blinded bias as low as possible. Throughout the study,
there will be two teams of physicians involved in the
patient’s follow-up. Physician 1 will perform the visits,
which include selection of patients, follow-up visits and
study end visit. Physician 1 will be kept blinded re-
garding the natures and doses of all study drugs admi-
nistered throughout the study. Physician 2 will perform
randomization and surgical procedure under general
anesthesia. However, physician 2 who is performing
anesthesia is not blinded due to technical reasons apply-
ing xenon anesthesia. However, the bias of physician 2,
who is aware of the randomization allocation, is kept
minimal. Physician 2 is not involved in the assessment
of the outcome parameters. Furthermore, the case report
forms are strictly separated and kept locked so physician
2 is not able to access the case report forms of physician
1 and vice versa.
Trial status
Patients are currently being recruited in all ten centers.
The study was initiated in September 2010 and the pre-
dicted study completion date is December 2013. To date,
121 patients have been randomized (July 2012).
Additional files
Additional file 1: Confusion Assessment Method (CAM)
questionnaire [20].
Additional file 2: Table S1. Sequental Organ Failure Score (SOFA)
[21,22].
Additional file 3: Table S2. Modified Aldrete Score [23].
Additional file 4: The 11-point verbal rating scale [24].
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